From the Guidelines
The patient with a UTI positive for Corynebacterium marius (50,000-100,000 CFU) who has received one dose of Cefepime 1g IM should complete a 7-day course of IV Cefepime.
Treatment Details
The recommended dosing would be Cefepime 1g IV every 12 hours for uncomplicated UTIs, or 2g IV every 12 hours for more severe infections, as supported by the guidelines for treating acute uncomplicated cystitis and pyelonephritis in women 1.
Considerations for Treatment
After clinical improvement (typically 2-3 days), consider transitioning to an appropriate oral antibiotic based on culture sensitivity results to complete the treatment course.
Monitoring and Adjustments
Ensure adequate hydration during treatment and monitor renal function, as dosage adjustments may be necessary for patients with impaired kidney function, as suggested by the principles of antimicrobial therapy 1.
Rationale for Choice of Antibiotic
Cefepime is effective against Corynebacterium species because it's a fourth-generation cephalosporin with broad-spectrum activity against both gram-positive and gram-negative bacteria, including many drug-resistant strains.
Completion of Treatment
Complete the full course of antibiotics even if symptoms improve to prevent recurrence and antimicrobial resistance, a key principle in the management of urinary tract infections 1.
From the FDA Drug Label
Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli, K. pneumoniae, or P. mirabilis† 0. 5 to 1 gIV/IM¶ Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli or K. pneumoniae† 2 g IV Every 12 hours 10
The patient is receiving one dose of Cefepime 1 g IM, and the UTI is positive for E. coli with a count of 50,000 to 100,000.
- The patient's condition can be classified as a complicated UTI.
- The recommended dosage for complicated UTIs due to E. coli is 0.5 to 1 g IV/IM every 12 hours for 7 to 10 days for mild to moderate infections, or 2 g IV every 12 hours for 10 days for severe infections.
- Since the count is 50,000 to 100,000, this can be considered a moderate infection.
- The patient should receive IV Cefepime for 7 to 10 days 2.
From the Research
Treatment of UTI with Cefepime
- The patient has a UTI positive for courteous Marius 50,000 to 100,000 and is receiving one dose of Cefepime 1 g IM.
- To determine the number of days of IV Cefepime the patient should receive, we need to consider the severity of the infection and the patient's response to treatment.
- According to the study 3, carbapenem-sparing antibiotics such as cefepime can be considered for milder infections, including urinary tract infections.
- However, the study 3 also notes that more reliable data are needed to recommend non-carbapenem antibiotics confidently for certain types of infections.
Cefepime Pharmacokinetics and Efficacy
- Cefepime is a fourth-generation cephalosporin with broad-spectrum activity against Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa 4.
- The study 5 shows that cefepime can penetrate the cerebrospinal fluid (CSF) and achieve adequate concentrations for the treatment of CNS infections.
- However, the optimal duration of IV Cefepime treatment for UTI is not explicitly stated in the provided studies.
Resistance and Treatment Considerations
- The study 6 highlights the importance of considering resistance patterns when selecting antibiotics, as overexpression of efflux systems can lead to resistance to multiple classes of antibiotics, including cefepime.
- The study 7 shows that Aeromonas strains, including A. hydrophila, are generally susceptible to cefepime, but resistance patterns can vary depending on the region and specific strain.